-
Priority review for Sanofi, Regeneron’s Dupixent
pharmatimes
November 08, 2018
Sanofi and Regeneron’s biologic Dupixent has been granted a priority review in the US for use to treat certain adolescent patients with moderate-to-severe atopic dermatitis.
-
Sanofi signs $1bn drug development deal with Denali Therapeutics
pharmaceutical-technology
November 06, 2018
Sanofi has entered a deal valued at more than $1bn with US-based Denali Therapeutics to advance potential drug candidates for the treatment of neurological and systemic inflammatory diseases.
-
Sanofi pays Denali $125M to buy into RIPK1 program 2. Biotech Sanofi pays Denali $125M to buy into RIPK1 program
fiercebiotech
November 02, 2018
Sanofi is?paying?$125 million (€110 million) upfront for a stake in two RIPK1 inhibitors in development at Denali. The agreement covers small molecules designed to treat multiple...
-
Sanofi's dengue shot Dengvaxia wins FDA priority review despite controversial past
fiercepharma
October 31, 2018
Sanofi has weathered controversy with its world-first dengue vaccine, Dengvaxia, but the company is pressing ahead, and on Tuesday said the FDA had not only accepted its application for approval, but also granted a priority review.
-
Sanofi's Dupixent set for $2.5B in peak asthma sales after scoring winning label
fiercepharma
October 23, 2018
Even as its diabetes unit struggles, Sanofi has made strides on the market with Dupixent since launching last year in eczema.
-
FDA approves Regeneron, Sanofi's Dupixent for asthma treatment
biospectrum
October 23, 2018
Regeneron and Sanofi recognize that DUPIXENT can only help those uncontrolled moderate-to-severe AD patients that were prescribed the medicine if they can both access the medicine and use it properly.
-
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials
October 19, 2018
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis...
-
Sanofi, Regeneron's Dupixent hits main goals of two late-stage studies for chronic rhinosinusitis with nasal polyps
biospectrumasia
October 17, 2018
Top Story Dupixent Regeneron Sanofi Clinical Research (R&D)
-
Sanofi backs 'The 16 vaccine' campaign to bolster meningitis booster awareness
fiercepharma
September 25, 2018
Most 16-year-olds are learning to drive, getting jobs and thinking about college and the future, but most likely are not thinking about vaccinations. Sanofi Pasteur and the National Meningitis Association want to change that with ...
-
Sanofi's Dupixent improves symptoms for adolescent atopic dermatitis patients
pharmafile
September 20, 2018
Sanofi’s Dupixent (dupilumab) has made a strong showing as a monotherapy at Phase 3 in the treatment of moderate-to-severe atopic dermatitis in patients...
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
